Median Technologies will participate in the European Congress of Radiology (ECR) 2022, July 13-17, 2022, Vienna, Austria, with two presentations on iBiopsy®


Median Technologies (ALMDT) (Paris:ALMDT) announces today that the Company will participate in the European Congress of Radiology (ECR) 2022, to be held in Vienna, Austria, from July 13-17.

The Society will make an industry presentation and a presentation of scientific papers. Session details include:

Industry Overview:Enabling lung cancer screening with iBiopsy® AI-based software as a medical device »

Session: AIX Theater

Date: July 13, 2022

Time: 3:25 p.m. – 3:45 p.m. CEST

Presentation of a scientific article: RPS 1305-6 – “Development and validation of a machine learning-based CADx designed to improve patient management in lung cancer screening programs”

Session: RPS 1305 – Artificial Intelligence (AI) in chest imaging: part 2

Categories: Artificial Intelligence and Machine Learning, Imaging Computing, Breast, Oncology Imaging

Date: July 15, 2022

Time: 10:30 a.m. – 12:00 p.m. CEST

Median’s team will be available at booth #AI-29, Expo X1, AI area to discuss presentations and showcase the latest developments on iBiopsy® LCS CADe/CADx SaMD July 13-17, 9:00am-5:00pm.

The European Congress of Radiology (ECR) organized by the European Society of Radiology (ESR) is the leading European event in radiology and the second in the world. The congress brings together over 20,000 people with a distribution of over 10,000 professional delegates (radiologists, technologists, etc.) and ~8,000 industry participants (imaging modalities, PACS, etc.). Radiology professionals from Europe and beyond attend to gain knowledge through training courses, to see the latest innovations from technical exhibitors, and to learn about groundbreaking research from scientific paper presentations. Learn more about the ECR:

About iBiopsy®: iBiopsy® relies on the most advanced technologies in Artificial Intelligence (AI) and Data Science (DS), benefiting from Median’s expertise in medical image processing. iBiopsy® aims at the development of an innovative software based on AI/ML as a medical device, to be used in several indications for which there are unmet needs for early diagnosis, prognosis and treatment selection in the context of precision medicine. iBiopsy® currently focuses on lung cancer, liver cancer (HCC) and liver fibrosis (NASH).

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for all. We harness the power of medical images using the most advanced artificial intelligence technologies, to increase the accuracy of the diagnosis and treatment of many cancers and other metabolic diseases in their early stages and provide information on new therapies for patients. . Our iCRO ​​solutions for the analysis and management of medical images in oncology trials and iBiopsy®, our software powered by AI as a medical device, help biopharmaceutical companies and clinicians bring new treatments and diagnose patients earlier and more accurately. This is how we help create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the United States and another in Shanghai, Median has been awarded the “Innovative Company” label by the BPI and is listed on the Euronext Growth market (Paris). FR0011049824 – Mnemo: ALMDT. Median is eligible for the PEA-PME, is part of the Enternext® PEA-PME 150 index and has obtained the Euronext European Rising Tech label. For more information:

1 An X-ray CAD device is “intended to identify, mark, highlight, or otherwise draw attention to portions of an image which may reveal abnormalities in the clinician’s interpretation of the images.” A CADx device is “intended to provide information beyond the identification of abnormalities, such as an assessment of disease. Source: FDA

Back To Top